Ziwei HUANG, Ph.D.
Professor Cheung Kong Scholar
1982-1986 B.S. South China Normal University, Guangzhou
1988-1993 Ph.D. University of California, San Diego, CA
1993-1994 Postdoc University of California, San Francisco, CA
1995-2000 Assistant Professor, Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
2000-2004 Associate Professor (Tenured), Departments of Biochemistry and Chemistry, University of Illinois at Urbana-Champaign, IL
2004-2009 Professor, Sanford-Burnham Medical Research Institute, La Jolla, CA
2005-2011 Adjunct Professor, School of Medicine, University of California, San Diego, CA
2009-2013 Professor (Tenured) and Chairman of Department of Pharmacology, Associate Vice President for Research Partnerships and International Collaborations, Director of Upstate Cancer Research Institute, Director of New York Center for Drug Discovery and Development, State University of New York, Upstate Medical University, Syracuse, NY
2013-present Professor (Tenured), School of Life Sciences, Tsinghua University, Beijing
Chemical Biology, Biochemistry and Structural Biology, Genomics and Proteomics, Stem Cell and Regenerative Medicine, Systems Biology and Pharmacology, Translational Medicine
Cancer, Neurological disorders, Autoimmune diseases, AIDs and Other Infectious Diseases, New Drug Discovery, Medicinal Chemistry, Peptide Chemistry, New Drug Design and Development, Computer-aided Drug Design, High-throughput Screening, Peptide and Small Molecule Design and Synthesis, Nanomedicine
● Krieg A, Correa RG, Garrison JB, Negrate GL, Welsh K, Huang Z, Knoefel WT and Reed JC. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. USA, 2009, 106:14524-9.
● Hu Q, Nie A, Welsh K, Crisóstomo FR, Zhu X, Li Z, An J, Reed JC, Zhang L and Huang Z*. Novel XIAP inhibitors as probes of apoptosis in biology and medicine. Exp. Biol. Med., 2011, 236:247-51.
● Choi WT, Kumar S, Madani N, Tian S, Dong CZ, Liu D, Yuan J, Sodroski JG, Huang Z* and An J. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. Biochemistry, 2012, 51:7078-86.
● Xu Y, Duggineni S, Espitia S, Richman DD, An J, and Huang Z*. A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem. Biophys. Res. Commun., 2013, 435:646-50.
● Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, An J, Pasquale EB, and Huang Z*. Design, synthesis and characterization of novel small molecular inhibitors of Ephrin-B2 binding to EphB4. Biochem. Pharmacology, 2013, 85:507-13.